These collaborations represent a significant step forward in advancing embolotherapy for chronic musculoskeletal pain by combining world-class clinical expertise with a scalable outpatient care ...

Through this relationship, Lumonus will license and co-develop MSK's ECHO mathematical optimization engine into the Lumonus platform and will invest in joint research focused on advancing automated ...

Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging cancer therapies. Their results, published in the ...

The irony is inescapable. What happens when a benefits broker is actually stricken by one of the most debilitating and costly ailments that participants in any one of the group health plans sold to ...

Chronic musculoskeletal (MSK) pain is a global problem, affecting approximately 1.7 billion people worldwide, according to the World Health Organization (WHO). Lower back pain, an MSK condition, is ...

Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in a variety of cancer treatments in 2025 — including new approaches to immunotherapy, targeted therapy, and surgical imaging ...

A new peer-reviewed study shows that a large, risk-bearing provider group reduced MSK-related healthcare costs by 81%, saving nearly $9 million in 20 months - by delivering Apos, a non-invasive, ...

Care Market OverviewThe global digital musculoskeletal (MSK) care market is poised for robust expansion, with an anticipated ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared a promising treatment option for bladder cancer patients today at The European Society for Medical Oncology (ESMO) Congress 2022.